Business Wire

CA-VECTARA

26.3.2024 14:01:31 CET | Business Wire | Press release

Share
Vectara Launches Factual Consistency Score Powered by Upgraded Hughes Hallucination Evaluation Model to Enhance Transparency in GenAI Responses

Vectara, the trusted Generative AI product platform, announced the inclusion of a Factual Consistency Score (FCS) for all generative responses based on an evolved version of the groundbreaking Hughes Hallucination Evaluation Model (HHEM)—the #1 hallucination detection model on Hugging Face with 100,000+ downloads since its launch last November. The associated Hallucination Leaderboard is now the industry standard for how LLMs benchmark their average factual consistency. Vectara’s end-to-end Retrieval Augmented Generation-as-a-service (RAGaaS) platform is setting a new standard as an industry-first feature for GenAI response transparency by providing real-time end-to-end RAG observability. This innovative metric provides unprecedented visibility into the factual consistency of summarized responses within Vectara’s RAGaaS platform, empowering users to set personalized thresholds for response acceptance based on a detailed accuracy score.

With average hallucination rates of LLMs on the market ranging from 3% to 16.2%, the risk of unknown inaccuracies in their response remains a major concern, preventing widespread business adoption of this powerful technology. Vectara mitigates this ambiguity for enterprises by providing a Factual Consistency Score grading the likelihood that the generated response is a hallucination or not. Only with a standardized, scientifically calculated method for grading responses can businesses responsibly introduce GenAI into business critical applications. Users have the ability to set thresholds for response acceptance based on a detailed accuracy score, giving product teams the flexibility to act on this information according to their preferences.

Vectara’s Factual Consistency Score is a groundbreaking tool in GenAI, setting a new benchmark for real-time hallucination detection and offering superior performance, affordability, and speed, thus marking a significant leap forward in trust. Its efficiency and effectiveness enable businesses to deploy GenAI into critical product use cases without being worried about exposure to liabilities that might arise from hallucinated responses.

Vectara's Factual Consistency Score equips developers with the capability to refine and enhance a wide range of applications, from internal Q&A systems to the quality of interactions with end consumers. The strength of this score lies in its calibration, making it interpretable as a direct probability—for instance, a score of 0.98 indicates a 98% probability of factual consistency. This contrasts sharply with many contemporary ML classifiers that disregard calibration, thus sacrificing clarity and direct interpretability.

"Integrating Vectara's Factual Consistency Score into the Yobi app will revolutionize how we handle AI transparency and accuracy for business use cases. By providing visibility and accountability into answers provided by our platform, we can stay true to our commitment to responsible AI that enterprises can depend on,” said Ahmed Reza, Founder and CEO of the Yobi app. “As a Co-Innovate Partner with Vectara, we're thrilled to see such advanced technology directly incorporated into the Vectara platform.”

The advanced HHEM that powers the Factual Consistency Score gives greater visibility than previously released open-sourced versions, offering enhanced accuracy and extended language support. This initiative is part of Vectara's commitment to transparency and control, empowering businesses with the autonomy to manage AI responses effectively.

"Just as we were early in pioneering RAG to enhance the relevance and quality of generated content, we are once again at the forefront of responsible AI by being completely open about our efforts to mitigate hallucinations in Generative AI," said Amr Awadallah, co-founder and CEO of Vectara. "By providing our customers with real-time access to factual consistency scores, we're not just engineering trust; we're handing over the control, enabling them to make informed decisions on how to utilize the responses generated by our RAGaaS platform."

About Vectara

Vectara is an end-to-end platform for embedding powerful generative AI features into applications with extraordinary results. As an end-to-end Retrieval Augmented Generation (RAG) platform, Vectara delivers the shortest path to a correct answer/action through a safe, secure, and trusted entry point. Vectara never trains on your data, allowing businesses to embed generative AI capabilities without the risk of data or privacy violations. To learn more, visit vectara.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240326712242/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release

Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin

Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release

Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer

TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press release

Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the

Andersen Consulting styrker sine kompetencer inden for digital transformation med Weexa1.5.2026 10:07:00 CEST | Pressemeddelelse

Andersen Consulting indgår en samarbejdsaftale med Weexa, en global leverandør af løsninger inden for digital transformation, B2B-integration og digitalisering af forsyningskæden. Med hovedsæde i Frankrig leverer Weexa end-to-end-tjenester, der hjælper organisationer med at optimere, sikre og skalere deres digitale økosystemer. Virksomheden specialiserer sig i styring af B2B-datastrømme og digitalisering, hvilket muliggør problemfri kommunikation mellem applikationer både internt og på tværs af organisationer gennem teknologier som EDI, API'er og e-fakturering. Weexa tilbyder også SAP-integration og supply chain-løsninger til styring af lager og transport, sideløbende med strategisk rådgivning, projektlevering og vedligeholdelse af tredjepartsapplikationer. Weexa betjener organisationer inden for fødevaresektoren, detailhandel, engros, logistik, transport, bilindustrien, sundheds- og mediesektoren og hjælper globale virksomheder med at optimere deres ydeevne samt at overholde de nyeste

Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release

Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye